Before a medical device reaches FDA or CE review, it needs early clinical data, and where that data gets generated matters. Early feasibility and first-in-human trials in Australia are faster to start, less expensive to run, and the resulting data holds up in US and EU submissions.
For many MedTech companies, Australia has become the preferred destination for early-stage clinical research. Here’s why.
- Lower Overall Costs. Running an early feasibility or first-in-human trial in Australia costs less than running the same trial in the US, driven by lower operational costs and a favorable AUD/USD exchange rate.
- Cash Back Through R&D Tax Incentives. Many trials qualify for Australia’s R&D Tax Incentive program, with potential cash rebates of up to 48%.
- Enrollment Starts Within Weeks, Not Months. First patient enrollment is often possible within 5 to 12 weeks of a completed protocol, accelerating the move from paperwork to an active study.
- A Five to Seven Day Regulatory Pathway. Australia’s Therapeutic Goods Administration(TGA) Clinical Trial Notification (CTN) scheme typically clears in 5-7 days, well ahead of the FDA approval pathway.
- A Single, Fast Ethics Review. Human Research Ethics Committees (HRECs) act as a harmonized primary review body, often responding within days and approving within about 30 days (some meet weekly). Governance approval can run in parallel with HREC review to save even more time.
- FDA-Accepted Data. Data generated in Australia is accepted by FDA in support of IDE, 510(k), De Novo, and PMA submissions.
- No FDA IDE Required to Start. No FDA IDE is required to commence a MedTech product clinical trial in Australia, removing a common barrier for international sponsors and substantially reducing regulatory complexity and timelines for early-phase studies.
- Infrastructure Built for Complex Studies. Advanced health facilities, imaging services, and clinical research infrastructure support studies at a world-class standard.
- Internationally Recognized Standards. Studies are conducted in accordance with ICH-GCP and ISO 14155, standards regulators recognize globally.
- Deep Access to Investigators and KOLs. Established clinical trial networks connect sponsors to experienced investigators and key opinion leaders who support study quality and recruitment.
- Strong Public-Private Collaboration. Public and private institutions work closely together, smoothing execution at every stage of a study.
- A Real Recruitment Advantage. Diverse patient populations, large patient pools, and fewer competing studies make enrollment faster and more predictable.
Planning an early feasibility study? Talk with Avania’s Australia team to evaluate whether Australia is the right first step for your clinical development program. AUSinfo@avaniaclinical.com